MA27565A1 - Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur - Google Patents

Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur

Info

Publication number
MA27565A1
MA27565A1 MA28335A MA28335A MA27565A1 MA 27565 A1 MA27565 A1 MA 27565A1 MA 28335 A MA28335 A MA 28335A MA 28335 A MA28335 A MA 28335A MA 27565 A1 MA27565 A1 MA 27565A1
Authority
MA
Morocco
Prior art keywords
tetrazolyl
treatment
methods
phenylpiperidine
pain
Prior art date
Application number
MA28335A
Other languages
English (en)
Inventor
Zhengming Chen
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MA27565A1 publication Critical patent/MA27565A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de 4-tétrazolyl-4-phénylpipéridine, des compositions contenant une quantité efficace d'un composé de 4-tétrazolyl-4-phénylpipéridine, ainsi que des procédés pour traiter et prévenir la douleur ou la diarrhée chez un animal. Lesdits procédés consistent à administrer à un animal, nécessitant un tel traitement, une quantité efficace d'un composé de 4-tétrazolyl-4-phénylpipéridine. L'invention concerne également des procédés pour stimuler la fonction de récepteurs opioïdes dans une cellule, lesdits procédés consistant à mettre en contact une cellule pouvant exprimer un récepteur opioïde avec une quantité efficace d'un composé de 4-tétrazolyl-4-phénylpipéridine.
MA28335A 2002-11-18 2005-06-13 Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur MA27565A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42738102P 2002-11-18 2002-11-18
US46027803P 2003-04-03 2003-04-03
US48848803P 2003-07-17 2003-07-17
US10/714,066 US7202259B2 (en) 2002-11-18 2003-11-13 Therapeutic agents useful for treating pain

Publications (1)

Publication Number Publication Date
MA27565A1 true MA27565A1 (fr) 2005-10-03

Family

ID=32777221

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28335A MA27565A1 (fr) 2002-11-18 2005-06-13 Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur

Country Status (37)

Country Link
US (3) US7202259B2 (fr)
EP (2) EP1803718B1 (fr)
JP (2) JP4601429B2 (fr)
KR (1) KR20050115221A (fr)
CN (2) CN100567288C (fr)
AP (1) AP2210A (fr)
AR (1) AR047008A1 (fr)
AT (2) ATE358674T1 (fr)
AU (2) AU2003294313B2 (fr)
BR (1) BR0316305A (fr)
CA (1) CA2506242C (fr)
CO (1) CO5690588A2 (fr)
CR (2) CR7877A (fr)
CY (2) CY1107682T1 (fr)
DE (2) DE60313021T2 (fr)
DK (2) DK1803718T3 (fr)
EA (1) EA008621B1 (fr)
EC (1) ECSP055840A (fr)
ES (2) ES2312150T3 (fr)
GE (1) GEP20084539B (fr)
HK (1) HK1086829A1 (fr)
IL (1) IL209352A0 (fr)
IS (2) IS2720B (fr)
MA (1) MA27565A1 (fr)
ME (1) MEP48108A (fr)
MX (1) MXPA05004669A (fr)
MY (1) MY135647A (fr)
NI (1) NI200500087A (fr)
NO (1) NO20052894L (fr)
NZ (2) NZ572685A (fr)
OA (1) OA13010A (fr)
PT (2) PT1562932E (fr)
RS (1) RS51047B (fr)
SG (1) SG165998A1 (fr)
SI (2) SI1562932T1 (fr)
TW (2) TW200819436A (fr)
WO (1) WO2004046132A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
CA2522529C (fr) 2003-04-30 2015-10-20 Purdue Pharma L.P. Forme de dosage transdermique inviolable
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
CA2720312A1 (fr) * 2004-01-30 2005-08-18 Euro-Celtique S.A. Procedes d'elaboration de composes de 4-tetrazolyl-4-phenylpiperidine
SE0401656D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
UA91250C2 (en) * 2005-11-21 2010-07-12 Пердью Фарма Л.П. 4-oxadiazolyl-piperidine compounds and use thereof
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
CA2810356C (fr) 2010-09-21 2016-06-14 Purdue Pharma L.P. Analogues de buprenorphine
CN102648915B (zh) * 2011-02-28 2015-04-15 鲁南制药集团股份有限公司 一种治疗或预防神经病理性疼痛的药物组合物
WO2012149334A2 (fr) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Procédés et compositions pour préparer et utiliser des anticorps spécifiques à une conformation
EP3333156A3 (fr) 2012-11-09 2018-09-26 Purdue Pharma L.P. Analogues de benzomorphane et leur utilisation
JP6317755B2 (ja) 2012-12-07 2018-04-25 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド受容体モジュレーターとしてのブプレノルフィン類似体
US8980906B2 (en) 2012-12-14 2015-03-17 Purdue Pharma L.P. Pyridonemorphinan analogs and biological activity on opioid receptors
JP6141444B2 (ja) 2012-12-14 2017-06-07 パーデュー、ファーマ、リミテッド、パートナーシップ スピロ環式モルフィナンおよびこれらの使用
CA2900023A1 (fr) 2013-01-31 2014-08-07 Purdue Pharma L.P. Analogues de benzomorphane et leur utilisation
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
WO2015097548A1 (fr) 2013-12-26 2015-07-02 Purdue Pharma L.P. Analogues 7-bêta-alkyle d'orvinols
US9340542B2 (en) 2013-12-26 2016-05-17 Purdue Pharma L.P. Propellane-based compounds and the use thereof
EP3087073B1 (fr) 2013-12-26 2018-07-04 Purdue Pharma LP Hydantoïnes de morphinane substitués en position 10
EP3087079B1 (fr) 2013-12-26 2019-04-03 Purdue Pharma LP Morphinanes oxabicyclo[2.2.2]octane modulateurs des récepteurs aux opiacés
AU2014370062A1 (en) 2013-12-26 2016-08-11 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
EP3086790A4 (fr) 2013-12-27 2017-07-19 Purdue Pharma LP Analogues de la morphinane 6-substitués et 7-substitués, et leurs utilisations
CA2950567A1 (fr) 2014-05-27 2015-12-03 Purdue Pharma L.P. Morphinanes spirocycliques et utilisation associee
EP3154972A4 (fr) 2014-06-13 2017-11-22 Purdue Pharma L.P. Dérivés d'azamophinan et leur utilisation
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
JP2019509321A (ja) 2016-03-22 2019-04-04 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 疼痛を処置するための組み合わせ
PE20190403A1 (es) 2016-07-29 2019-03-13 Janssen Pharmaceutica Nv Metodos para tratar el cancer de prostata
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof
MX2023013514A (es) * 2021-05-21 2024-04-02 Purdue Pharma Lp Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
WO2023250190A1 (fr) * 2022-06-24 2023-12-28 Purdue Pharma L.P. Méthodes de traitement ou de prévention du syndrome de la vessie hyperactive

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
BE775611A (fr) 1970-11-24 1972-03-16 Synthelabo Derives de la (diphenyl-3,3 propyl-1)-1 piperidine, leur preparation etles medicaments qui en contiennent
US4076717A (en) * 1971-12-15 1978-02-28 G. D. Searle & Co. Derivatives of 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DK162087D0 (da) * 1987-03-31 1987-03-31 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
US4831192A (en) * 1987-12-31 1989-05-16 Boc, Inc. Methods of preparing 4-heteropentacyclic-4-(N-phenyl)amido) piperidine derivatives and intermediate compounds
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5449989A (en) 1992-07-31 1995-09-12 Correa; Paulo N. Energy conversion system
US5736523A (en) 1992-11-09 1998-04-07 Biochem Pharma Inc. Antineoplastic heteronapthoquinones
US5606037A (en) 1992-11-09 1997-02-25 Biochem Pharma Inc. Processes antineoplastic heteronaphthoquinones
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6166085A (en) 1995-04-14 2000-12-26 The Regents Of The University Of California Method of producing analgesia
US5849737A (en) 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
ES2247604T3 (es) 1995-06-12 2006-03-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa.
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
AU1208397A (en) 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
DE29724281U1 (de) * 1997-06-10 2000-08-10 Synthon Bv 4-Phenylpiperidin-Verbindungen
IL138227A0 (en) 1998-03-06 2001-10-31 Janssen Pharmaceutica Nv Glycine transport inhibitors
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
KR100709497B1 (ko) 1999-03-12 2007-04-20 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 소염제로서 유용한 화합물 및 이의 제조방법
AU7315800A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Mch antagonists
CA2324330A1 (fr) 1999-11-08 2001-05-08 Ssp Co., Ltd. Derives de la 4-hydroxy-4-phenylpiperidine et produits pharmaceutiques a base de ceux-ci
US7456198B2 (en) 1999-12-06 2008-11-25 Purdue Pharma L.P. Benzimidazole compounds having nociceptin receptor affinity
EP1244678A1 (fr) 1999-12-22 2002-10-02 Merck Frosst Canada Inc. DERIVES D'ACIDE PHOSPHONIQUE EN TANT QU'INHIBITEURS DE LA PROTEINE TYROSINE PHOSPHATASE 1$g(b) (PTP-1$g(b))
US6703525B2 (en) 2000-02-16 2004-03-09 Boehringer Ingelheim Pharmaceuticals, Inc. Sulfonamide intermediates and methods of producing same
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
AU4274401A (en) 2000-03-24 2001-10-03 Meiji Seika Kaisha Diphenylalkylamine derivatives useful as opioid delta receptor agonists
US6544981B2 (en) 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
KR20030043970A (ko) 2000-10-12 2003-06-02 에스에스 세야쿠 가부시키 가이샤 2,2-디페닐부탄아미드 유도체 및 이를 함유하는 의약
AU2002226000A1 (en) 2000-11-13 2002-05-21 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
CA2720312A1 (fr) 2004-01-30 2005-08-18 Euro-Celtique S.A. Procedes d'elaboration de composes de 4-tetrazolyl-4-phenylpiperidine

Also Published As

Publication number Publication date
ES2285235T3 (es) 2007-11-16
MXPA05004669A (es) 2005-06-08
EP1562932A1 (fr) 2005-08-17
JP2010163452A (ja) 2010-07-29
US7202259B2 (en) 2007-04-10
WO2004046132A1 (fr) 2004-06-03
NZ540068A (en) 2007-07-27
MEP48108A (en) 2011-02-10
SI1803718T1 (sl) 2008-12-31
CR11037A (es) 2009-10-29
US20040152689A1 (en) 2004-08-05
CN100567288C (zh) 2009-12-09
US20100069437A1 (en) 2010-03-18
AU2003294313B2 (en) 2010-08-26
EA008621B1 (ru) 2007-06-29
AU2010246411A1 (en) 2010-12-16
NI200500087A (es) 2007-07-24
EA200500726A1 (ru) 2005-10-27
NO20052894D0 (no) 2005-06-14
ECSP055840A (es) 2005-08-11
JP4601429B2 (ja) 2010-12-22
NZ572685A (en) 2010-06-25
ES2312150T3 (es) 2009-02-16
SI1562932T1 (sl) 2007-08-31
DE60313021D1 (de) 2007-05-16
TWI343917B (en) 2011-06-21
CA2506242A1 (fr) 2004-06-03
IS8913A (is) 2010-07-21
PT1562932E (pt) 2007-07-02
ATE358674T1 (de) 2007-04-15
IL209352A0 (en) 2011-01-31
US8026254B2 (en) 2011-09-27
AP2210A (en) 2011-02-25
KR20050115221A (ko) 2005-12-07
DE60322451D1 (de) 2008-09-04
PT1803718E (pt) 2008-09-26
TW200819436A (en) 2008-05-01
HK1086829A1 (en) 2006-09-29
CN101648941A (zh) 2010-02-17
IS2720B (is) 2011-02-15
IS7812A (is) 2005-04-19
EP1562932B9 (fr) 2007-09-12
EP1803718B1 (fr) 2008-07-23
CN1711256A (zh) 2005-12-21
CA2506242C (fr) 2011-07-05
EP1562932B1 (fr) 2007-04-04
US20070179141A1 (en) 2007-08-02
RS51047B (sr) 2010-10-31
AP2005003297A0 (en) 2005-06-30
JP2006525944A (ja) 2006-11-16
GEP20084539B (en) 2008-11-25
EP1803718A1 (fr) 2007-07-04
AU2003294313A1 (en) 2004-06-15
NO20052894L (no) 2005-06-14
ATE402167T1 (de) 2008-08-15
CY1107682T1 (el) 2013-04-18
MY135647A (en) 2008-06-30
US7687518B2 (en) 2010-03-30
OA13010A (en) 2006-11-10
AR047008A1 (es) 2006-01-04
RS20050375A (en) 2007-11-15
CY1108422T1 (el) 2014-04-09
DE60313021T2 (de) 2007-12-13
BR0316305A (pt) 2005-09-27
CR7877A (es) 2005-11-30
TW200418828A (en) 2004-10-01
DK1803718T3 (da) 2008-10-27
SG165998A1 (en) 2010-11-29
DK1562932T3 (da) 2007-08-13
CO5690588A2 (es) 2006-10-31

Similar Documents

Publication Publication Date Title
MA27565A1 (fr) Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur
MA28681B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
MA29915B1 (fr) Benzimidazoles substitues utilises en tant qu'inhibiteurs de kinases
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
TN2009000138A1 (fr) Biaryl-ether-urees
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
HK1074573A1 (en) Tetrahydroquinoline analogues as muscarinic agonists
MA32232B1 (fr) Nouveaux compoés hétérocycliques et leurs utilisations
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
TW200624430A (en) 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
EA200500392A1 (ru) Производные пиримидина и их применение в качестве модуляторов св2
ATE461196T1 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
MA30999B1 (fr) Composés.
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
MX2007003094A (es) 4-(metilo ciclico condensado)-imidazol-2-tionas como agonistas alfa2 adrenergicos.
MA30392B1 (fr) Composes organiques et leurs utilisations
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
TNSN98227A1 (fr) Association pharmaceutique pour le traitement d'un dysfonctionnement sexuel et compositions la contenant.
DE502004006619D1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ